Bahar Dasgeb is a Dermatology physician affiliated with Rutgers Cancer Institute. OpenAlex indexes 42 publications with 692 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
195 Little Albany St Dept Of
New Brunswick, NJ 089011914
Telephone
732-235-5120Provider last certified this registry record 11 Feb 2021.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20241 payment
- Regeneron Healthcare Solutions, Inc.Program year20221 payment
- Regeneron Pharmaceuticals, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
46.9%Corticosteroid25.5%Triamcinolone Acetonide100%Part D≥41 patientsAntivirals15.9%Imiquimod100%Part D≥23 patients+ 1 more class in this area
Anti-infectives
22.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor6.9%Valacyclovir100%Part D≥11 patientsTetracycline-class Drug6.6%Doxycycline Hyclate100%Part D≥14 patients+ 2 more classes in this area
Sensory organs
17.6%Corticosteroid17.6%Clobetasol Propionate100%Part D≥31 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Diagnosis and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
International Journal of Dermatology
2026 - Fairness aware subset selection for advancing equity in skin cancer detection
Journal of the American Medical Informatics Association
2026 - 0748 Synergy of TP53 and non-canonical sonic hedgehog pathway in the development of complex basal cell carcinoma
Journal of Investigative Dermatology
2025 - ROLE OF CIRCUMCISION IN OPTIMIZATION OF TOPICAL IMMIQUIMOD THERAPY FOR TREATMENT OF SQUAMOUS CELL CARCINOMA IN SITU OF THE GLANS PENIS
Urologic Oncology Seminars and Original Investigations
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Christian Hinrichs, MD
Rutgers Cancer Institute
Tina Mayer, MD
Rutgers Cancer Institute
Bo Qin
Rutgers Cancer Institute
Nicholas Denunzio, MD, PhD
Rutgers Cancer Institute
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”